Chin, K., Cai, S., Derkach, A., Melamed, G., Smith, N., Shukla, N., Zeidner, J., Aldoss, I., Issa, G., Stein, E. (2025). A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias. Blood. https://doi.org/10.1182/blood-2025-1657